Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion

Simple Summary Recently, innovative gene therapy has been developing toward functional restoration by gain of function or gene correction. Hemophilia is a representative genetic disorder with many human patients and is considered a candidate disease for gene therapy. The most frequent severe hemophilia A is caused by inversion mediated structural variation of the human F8 gene. Nevertheless, a mouse model with F8 intron 22 inversion is not developed yet. This study presents a novel hemophilia A mouse model with 319 kb inversion and severe coagulation disorder and could be utilized in future gene correction preclinical trials. Abstract Hemophilia A (HA) is an X-linked recessive blood coagulation disorder, and approximately 50% of severe HA patients are caused by F8 intron 22 inversion (F8I22I). However, the F8I22I mouse model has not been developed despite being a necessary model to challenge pre-clinical study. A mouse model similar to human F8I22I was developed through consequent inversion by CRISPR/Cas9-based dual double-stranded breakage (DSB) formation, and clinical symptoms of severe hemophilia were confirmed. The F8I22I mouse showed inversion of a 391 kb segment and truncation of mRNA transcription at the F8 gene. Furthermore, the F8I22I mouse showed a deficiency of FVIII activity (10.9 vs. 0 ng/mL in WT and F8I22I, p < 0.0001) and severe coagulation disorder phenotype in the activated partial thromboplastin time (38 vs. 480 s, p < 0.0001), in vivo bleeding test (blood loss/body weight; 0.4 vs. 2.1%, p < 0.0001), and calibrated automated thrombogram assays (Thrombin generation peak, 183 vs. 21.5 nM, p = 0.0012). Moreover, histological changes related to spontaneous bleeding were observed in the liver, spleen, and lungs. We present a novel HA mouse model mimicking human F8I22I. With a structural similarity with human F8I22I, the F8I22I mouse model will be applicable to the evaluation of general hemophilia drugs and the development of gene-editing-based therapy research.

[1]  H. Spencer,et al.  The Immune Response to the fVIII Gene Therapy in Preclinical Models , 2020, Frontiers in Immunology.

[2]  Mark E. Mahan,et al.  A rare case of spontaneous splenic rupture complicated by hemophilia A , 2019, Journal of surgical case reports.

[3]  M. Jamil,et al.  F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis , 2019, Front. Genet..

[4]  V. Arruda,et al.  Gene therapy for hemophilia: what does the future hold? , 2018, Therapeutic advances in hematology.

[5]  R. Peters,et al.  Advances and innovations in haemophilia treatment , 2018, Nature Reviews Drug Discovery.

[6]  J. Shendure,et al.  Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. , 2017, Blood advances.

[7]  N. Muzyczka,et al.  AAV: An Overview of Unanswered Questions. , 2017, Human gene therapy.

[8]  S. Upadhyaya,et al.  Spontaneous intracerebral hemorrhage in hemophiliacs—A treatment dilemma , 2016, International journal of surgery case reports.

[9]  Shu-Wha Lin,et al.  Current animal models of hemophilia: the state of the art , 2016, Thrombosis Journal.

[10]  Jin-Soo Kim,et al.  Cas-analyzer: an online tool for assessing genome editing results using NGS data , 2016, Bioinform..

[11]  D. Liang,et al.  In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs , 2016, Scientific Reports.

[12]  Jin-Soo Kim,et al.  Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. , 2015, Cell stem cell.

[13]  E. Roeder,et al.  Clinical characterization of int22h1/int22h2-mediated Xq28 duplication/deletion: new cases and literature review , 2015, BMC Medical Genetics.

[14]  Ya Guo,et al.  Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9 , 2015, Journal of molecular cell biology.

[15]  Jin-Soo Kim,et al.  Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs , 2014, Proceedings of the National Academy of Sciences.

[16]  P. Esposito,et al.  Renal diseases in haemophilic patients: pathogenesis and clinical management , 2013, European journal of haematology.

[17]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[18]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  A. Dart,et al.  Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. , 2012, World journal of experimental medicine.

[20]  M. Margaglione,et al.  F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. , 2012, Blood.

[21]  Eunji Kim,et al.  Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases. , 2012, Genome research.

[22]  E. Berntorp,et al.  Haemophilia and joint disease: pathophysiology, evaluation, and management , 2011, Journal of comorbidity.

[23]  J. G. van der Bom,et al.  Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  P. Collins,et al.  Liver haemorrhage in haemophilia – a case report and review of the literature , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  J. Oldenburg,et al.  Haemophilia A: from mutation analysis to new therapies , 2005, Nature Reviews Genetics.

[26]  A. Dutra,et al.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Giles,et al.  Aberrant Splicing and Premature Termination of Transcription of the FVIII Gene as a Cause of Severe Canine Hemophilia A: Similarities with the Intron 22 Inversion Mutation in Human Hemophilia , 2002, Thrombosis and Haemostasis.

[28]  D. Bowen.  Haemophilia A and haemophilia B: molecular insights , 2002, Molecular pathology : MP.

[29]  B. Evatt,et al.  Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  S. Antonarakis,et al.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.

[31]  H. I. . Thus.  INPATIENTS , 1972 .